ReviewDrug safety2018

Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.

Abril Verden et al.PubMed ↗Publisher ↗

No numbers read from the abstract.